Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2005

01-02-2005

It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer

In Reply

Authors: Angelos M. Kappas, MD, Michael Fatouros, MD, Dimitrios H. Roukos, MD

Published in: Annals of Surgical Oncology | Issue 2/2005

Login to get access

Excerpt

We thank the authors for their interest in our editorial published in the August issue of the Annals of Surgical Oncology1 and for their letter to the editor. They give us the opportunity to comment again on an extremely complicated topic. Does D2 over D1 dissection provide a survival benefit in patients with gastric cancer? Decades-long debate on this hot topic suggests how difficult and challenging it is to draw conclusions and make recommendations2 about an optimal extent of lymphadenectomy. …
Literature
1.
Kappas, AM, Fatouros, M, Roukos, DH 2004Is it time to change surgical strategy for gastric cancer in the United States?Ann Surg Oncol1172730
2.
Roukos, DH 2004Proof-of-concept changes treatment guidelines for gastric cancerGastric Breast Cancer3236
3.
Bonnenkamp, JJ, Hermans, J, Sasako, M, van de Velde, CJH 1999Extended lymph-node dissection for gastric cancerN Engl J Med34090814CrossRefPubMed
4.
Cuschieri, A, Weeden, S, Fielding, J,  et al. 1999Patient survival after D1 and D2 resection for gastric cancer: long-term results of the MRC randomised surgical trial. Surgical co-operation groupBr J Cancer79152230CrossRefPubMed
5.
Siewert, JR, Boettcher, K, Stein, HJ,  et al. 1998Relevant prognostic factors in gastric cancer. Ten-year results of the German Gastric Cancer StudyAnn Surg22844961
6.
Roukos, DH, Lorenz, M, Encke, A 1998Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up studySurgery1235738
7.
Roukos, DH 2000Extended (D2) lymph node dissection for gastric cancer: do patients benefit (editorial)?Ann Surg Oncol72535
8.
Roukos, DH 2002Optimizing lymph node dissection for gastric cancerGastric Breast Cancer1403
9.
Roukos, DH, Kappas, AM 2002Targeting the optimal extent of lymph node dissection for gastric cancer (guest editorial)J Surg Oncol815962
10.
Hartgrink, HH, van-de Velde, CJ, Putter, H,  et al. 2004Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trialJ Clin Oncol22206977
11.
Roukos, DH 2000Current status and future perspectives in gastric cancer managementCancer Treat Rev2624355
12.
Roukos, DH 1998Extended lymphadenectomy in gastric cancer: when, for whom and whyAnn R Coll Surg Engl801624
13.
Roukos, DH, Lorenz, M, Karakostas, K, Paraschou, P, Batsis, C, Kappas, AM 2001Pathological serosa and node-based classification accurately predicts gastric-cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patientsBr J Cancer8416029
14.
Nakajima, T 2002Gastric cancer treatment guidelines in JapanGastric Cancer515CrossRef
15.
Roukos, DH, Kappas, AM 2001Limitations in controlling risk of recurrence after curative surgery for advanced gastric cancer are now well-explained by molecular-based mechanisms (editorial)Ann Surg Oncol86201
16.
Roukos, DH 2004Early-stage gastric cancer: a highly treatable disease (editorial)Ann Surg Oncol111279
17.
Sano, T, Sasako, M, Yamamoto, S,  et al. 2004Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group Study 9501J Clin Oncol22276773
18.
Fatouros, M, Roukos, DH, Agnantis, NJ, Kappas, AM 2003Confirming hypothesis-driven surgical concept and comparing potential survival benefit expected by D2 surgery and adjuvant treatment (perspective)Gastric Breast Cancer23544
Metadata
Title
It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer
In Reply
Authors
Angelos M. Kappas, MD
Michael Fatouros, MD
Dimitrios H. Roukos, MD
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.11.914

Other articles of this Issue 2/2005

Annals of Surgical Oncology 2/2005 Go to the issue

Original Article

Isolated Hepatic Perfusion for the Treatment of Patients With Colorectal Cancer Liver Metastases After Irinotecan-Based Therapy

Editorial

Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Plea for Prospective Differentiation Between Main-Duct and Side-Branch Tumors

OriginalPaper

Hepatic Resection at a Major Community-Based Teaching Hospital Can Result in Good Outcome

Letters to the Editor

It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer

OriginalPaper

Multicenter Analysis of Clinicopathologic Features of Intraductal Papillary Mucinous Tumor of the Pancreas: Is It Possible to Predict the Malignancy Before Surgery?

Editorial

In Vivo Sentinel Lymph Node Mapping in Lung Cancer